Drug Patents owned by Palatin Technologies
1. Drug name - VYLEESI (AUTOINJECTOR)
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6794489 | PALATIN TECHNOLOGIES | Compositions and methods for treatment of sexual dysfunction |
Jun, 2025
(2 years from now) | |
| CN1988915A | PALATIN TECHNOLOGIES | Multiple Agent Therapy For Sexual Dysfunction |
Feb, 2010
(12 years ago) | |
| CN101010095A | PALATIN TECHNOLOGIES | Cyclic Peptide For Treating Cachexia |
Apr, 2011
(11 years ago) | |
| CN101010096A | PALATIN TECHNOLOGIES | Cyclic Peptide For Treating Cachexia |
Apr, 2011
(11 years ago) | |
| EP1196184B8 | PALATIN TECHNOLOGIES | Compositions For Treatment Of Sexual Dysfunction |
Jun, 2020
(2 years ago) | |
| EP1196184A4 | PALATIN TECHNOLOGIES | Compositions And Methods For Treatment Of Sexual Dysfunction |
Jun, 2020
(2 years ago) | |
| EP1196184B1 | PALATIN TECHNOLOGIES | Compositions For Treatment Of Sexual Dysfunction |
Jun, 2020
(2 years ago) | |
| EP1196184A1 | PALATIN TECHNOLOGIES | Compositions For Treatment Of Sexual Dysfunction |
Jun, 2020
(2 years ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9352013 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(11 years from now) | |
| US9700592 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(11 years from now) | |
| US10286034 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(11 years from now) | |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
Treatment: Treatment of hypoactive sexual desire disorder (hsdd)
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML) | SOLUTION;SUBCUTANEOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.